Rubella and congenital rubella (German measles)
Richard F Edlich1, Kathryne L Winters, William B Long
1Distinguished Professor Emeritus of Plastic Surgery and Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia, USA. richardedlichmd@gmail.com
Abstract:
Rubella, also known as German measles, is usually a very mild infection that can have devastating effects in certain instances. It is a pleomorphic RNA virus in the Togaviridae family of the genus Rubivirus. It typically causes a scarletiniform rash, cervical lymphadenopathy, and mild constitutional symptoms, but in older children and adults, especially women, it may be more severe, with joint involvement and purpuric rash. Infection during the first 12 weeks of pregnancy results in congenital infection and/or miscarriage in 80-90% of cases. The congenital rubella syndrome (CRS) involves multiple organ systems and has a long period of active infection and virus shedding in the postnatal period. For these reasons, the rubella vaccine program was instituted in 1969, and the incidence of rubella infection in the United States has since declined by 99%. Rubella has been recognized as a disease for approximately 200 years, and it has since been found that humans are the only natural reservoir for the rubella virus. Virus is present in nasopharyngeal secretions, blood, feces, and urine during the clinical illness, although patients with subclinical disease are also infectious. The virus is spread via oral droplets and is shed in the nasopharynx for approximately 7 days before and after the rash is visible. CRS includes a configuration of anomalies, including nerve deafness, cataracts, cardiac anomalies (usually pulmonary artery and valvular stenosis, and patent ductus arteriosis), and mental retardation, with late complications including diabetes, thyroid disease, growth hormone deficiency, and progressive panencephalitis. In 1969, the first rubella vaccine was licensed for use, and the Centers for Disease Control and Prevention (CDC) began its National Congenital Rubella Syndrome Registry. As required under the National Childhood Injury Act, all healthcare providers in the United States who administer any vaccine shall, prior to administration of the vaccine, provide a copy of the Vaccine Information Statements (VIS) produced by the CDC to the parent or legal representative of any child to whom the provider intends to administer such vaccine, or to any adult to whom the provider intends to administer such vaccine. Despite efforts to vaccinate children, CRS continues to occur in the United States. Hispanic infants have an increased risk of CRS. HIV-1infected children with a preserved immune system and MMR immunization had a good response to rubella vaccine. In contrast, those in more advanced categories for HIV infection responded poorly. Issues of risk, choice, and chance are central to the controversy over the MMR vaccine that erupted in the UK in 1998, and has continued into the new millennium. An important contribution to the MMR controversy has come from the parents of autistic children, some of whom reject the notion that this disorder is a random genetic misfortune and insist that it is, at least in part, the result of some environmental insult, such as MMR vaccinations.
Insights
Rubella (German measles) is a mild viral infection but can cause severe congenital rubella syndrome (CRS) in infants. Vaccination has drastically reduced rubella incidence, though challenges remain.
Area of Science:
- Virology
- Immunology
- Public Health
Background:
- Rubella, or German measles, is a mild RNA virus infection typically causing rash and mild symptoms.
- However, infection during early pregnancy leads to a high risk of miscarriage or congenital rubella syndrome (CRS) in infants.
- CRS can result in severe lifelong disabilities, including deafness, cataracts, and heart defects.
Purpose of the Study:
- To review the history, impact, and prevention of rubella and congenital rubella syndrome (CRS).
- To highlight the effectiveness of the rubella vaccine program instituted in 1969.
- To discuss ongoing challenges and controversies surrounding rubella vaccination.
Main Methods:
- Review of historical data on rubella incidence and CRS.
- Analysis of vaccine program effectiveness and impact on public health.
- Examination of current challenges, including vaccine hesitancy and specific population risks.
Main Results:
- The rubella vaccine program, initiated in 1969, has led to a 99% decline in rubella incidence in the United States.
- Despite vaccination efforts, CRS continues to occur, with Hispanic infants showing an increased risk.
- MMR vaccine response varies in HIV-1 infected children; those with preserved immunity respond better.
Conclusions:
- Rubella vaccination is highly effective in preventing rubella infection and CRS.
- Continued vaccination efforts are crucial to eradicate rubella and prevent congenital defects.
- Addressing vaccine hesitancy and understanding risks in vulnerable populations are essential for public health.
More Related Videos
05:51Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
Published on: July 24, 2016
09:39Establishing Mouse Models for Zika Virus-induced Neurological Disorders Using Intracerebral Injection Strategies: Embryonic, Neonatal, and Adult
Published on: April 26, 2018
Related Concept Videos
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Sexually Transmitted Infections
Rocky Mountain Spotted Fever
Rabies
Cytomegalovirus Disease
Respiratory Syncytial Virus Disease
